Analysis of Revenues
Revenues as Reported
Vertex Pharmaceuticals Inc., income statement, revenues
US$ in thousands
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
- Revenue Trends of TRIKAFTA/KAFTRIO
- There has been a consistent and significant upward trend in the revenue generated by TRIKAFTA/KAFTRIO from 2020 through 2024. Starting at approximately 3.86 billion US dollars in 2020, the revenue increased steadily each year to reach over 10.2 billion US dollars by 2024. This represents a growth of more than 2.6 times over the five-year period, indicating robust market demand and possibly successful product adoption or expansion.
- Other Product Revenues
- In contrast, revenues from other products showed a declining pattern over the same timeframe. Beginning at approximately 2.34 billion US dollars in 2020, these revenues fell each year, reaching around 0.78 billion US dollars in 2024. This decline suggests decreasing sales or possibly the phasing out of older products as newer offerings gain prominence.
- Overall Product Revenues, Net
- The net product revenues, which aggregate the revenues from TRIKAFTA/KAFTRIO and other products, display a positive upward trend despite the decline in other product revenues. The total net revenue increased from about 6.20 billion US dollars in 2020 to approximately 11.02 billion US dollars in 2024. This growth reflects the dominant contribution and strong performance of TRIKAFTA/KAFTRIO, more than compensating for the drop in revenue from other products.
- Summary of Insights
- The data indicates a strategic shift towards TRIKAFTA/KAFTRIO as the primary revenue driver, with its sales growth outpacing the decline in other product revenues. This shift suggests effective market positioning and possibly innovation focus. The overall positive revenue trajectory reflects successful commercial execution and product lifecycle management.